Lauren Merendino is Chief Commercial Officer of Day One Biopharmaceuticals, Inc.. Currently has a direct ownership of 35,161 shares of DAWN, which is worth approximately $246,127. The most recent transaction as insider was on May 16, 2025, when has been sold 3,927 shares (Common Stock) at a price of $6.26 per share, resulting in proceeds of $24,583. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 35.2K
n/a 3M change
n/a 12M change
Total Value Held $246,127

Lauren Merendino Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 16 2025
SELL
Open market or private sale
$24,583 $6.26 p/Share
3,927 Reduced 10.05%
35,161 Common Stock
May 15 2025
BUY
Exercise of conversion of derivative security
-
10,536 Added 21.23%
39,088 Common Stock

Also insider at

MYOV
Myovant Sciences Ltd. Healthcare
EPIX
ESSA Pharma Inc. Healthcare
LM

Lauren Merendino

Chief Commercial Officer
Brisbane, CA

Track Institutional and Insider Activities on DAWN

Follow Day One Biopharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DAWN shares.

Notify only if

Insider Trading

Get notified when an Day One Biopharmaceuticals, Inc. insider buys or sells DAWN shares.

Notify only if

News

Receive news related to Day One Biopharmaceuticals, Inc.

Track Activities on DAWN